BEIJING, June 29 /PRNewswire-Asia-FirstCall/ —
China Medical Technologies, Inc. (the “Company”) (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic
(“IVD”) company, today announced the recent publication of a large
sample study on the Company’s SPR analyzer and related HPV DNA chip
(the “SPR System”) for the detection of 16 high risk and 8 low risk
genotypes of human papillomavirus (“HPV”). The study tested
specimens of 560 patients with atypical squamous cells of
undetermined significance (“ASCUS”) or above using the SPR System
and compared the results with sequence analysis. The study
concluded that the SPR System is highly sensitive and specific in
HPV genotyping (99% concordance between the SPR System and sequence
analysis) and can become an effective approach for HPV genotyping
in a clinical setting.
The study is entitled, “A Surface Plasmon Resonance-based System
to Genotype Human Papillomavirus”, and can be found in the online
edition of the medical journal Cancer Genetics and Cytogenetics,
Volume 200, Issue 2, at http://cancergeneticsjournal.org
.
The Company also announced the creation of a new column “Medical
Publications” in its investor relations section at http://ir.chinameditech.com
which currentl
‘/>”/>
SOURCE
